Skip to main content

ttx-mc138

·Code: TTX-MC138, TTX-MC138-NODAGA-Cu64

ttx-mc138: sourced relationships with 1 company · 2 clinical trials tracked.

ttx-mc138 evidence translation

What we can confirm

What it means

Source-backed records connect ttx-mc138 to RNAZ; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could ttx-mc138 → RNAZ affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Transcode Therapeutics, Inc. (RNAZ)
developer · Reported 2026-04-15 · Current development: unknownSource
Advanced Solid Tumor
Phase 1/Phase 2
Clinical Trial Registry Records (2)

A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774Registry updated 2025-10-02·Phase 1/Phase 2·RNAZ

Primary endpoint: Dose Escalation - Adverse Events

Interventionalopen16 targetStarted 2024-09Completion 2027-024 sites · United StatesTransCode Therapeutics

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

NCT05868226Registry updated 2026-09-30·Phase 1/Phase 2
Recruiting

Primary endpoint: Incidence of Adverse Events related to the treatment

Interventionalopen280 targetStarted 2023-02Completion 2031-1210 sites · United StatesQuantumLeap Healthcare Collaborative

Frequently asked questions

Which companies have sourced relationships with ttx-mc138?

ttx-mc138 has dated SEC/FDA relationship records for Transcode Therapeutics, Inc..

How many clinical trials involve ttx-mc138?

BioSniper tracks 2 clinical trials involving ttx-mc138.